Published in Clinical Trials Week, December 6th, 2004
Researchers in the United States "performed a randomized prospective trial" comparing CNI-free "to CNI-based immunosuppression to determine the impact on renal function, structure and gene expression."
"Sixty-one kidney recipients treated with basiliximab mycophenolate mofetil (MMF) and prednisone (P) were randomly assigned to concentration-controlled sirolimus or cyclosporine," explained S.M. Flechner and coauthors at the Cleveland Clinic Foundation. "Two years post-transplant 55 patients underwent renal function studies, 48 (87%)...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.